CTi Biopharma Corp Valuation
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
At this time, the firm appears to be overvalued. CTi Biopharma Corp shows a prevailing Real Value of $6.66 per share. The current price of the firm is $9.09. Our model approximates the value of CTi Biopharma Corp from analyzing the firm fundamentals such as Profit Margin of (0.91) %, current valuation of 1.26 B, and Return On Equity of -10.19 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that CTi Biopharma's price fluctuation is very steady at this time. Calculation of the real value of CTi Biopharma Corp is based on 3 months time horizon. Increasing CTi Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for CTi Biopharma Corp is useful when determining the fair value of the CTi stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of CTi Biopharma. Since CTi Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CTi Stock. However, CTi Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.09 | Real 6.66 | Hype 9.09 |
The real value of CTi Stock, also known as its intrinsic value, is the underlying worth of CTi Biopharma Corp Company, which is reflected in its stock price. It is based on CTi Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of CTi Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence CTi Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of CTi Biopharma Corp helps investors to forecast how CTi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CTi Biopharma more accurately as focusing exclusively on CTi Biopharma's fundamentals will not take into account other important factors: CTi Biopharma Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining CTi Biopharma's current stock value. Our valuation model uses many indicators to compare CTi Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CTi Biopharma competition to find correlations between indicators driving CTi Biopharma's intrinsic value. More Info.CTi Biopharma Corp is rated below average in price to earning category among related companies. It is number one stock in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value CTi Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CTi Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CTi Biopharma's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CTi Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CTi Biopharma and how it compares across the competition.
About CTi Biopharma Valuation
The delisted stock valuation mechanism determines the current worth of CTi Biopharma Corp on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of CTi Biopharma Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of CTi Biopharma Corp based exclusively on its fundamental and basic technical indicators. By analyzing CTi Biopharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of CTi Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of CTi Biopharma. We calculate exposure to CTi Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CTi Biopharma's related companies.CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
8 Steps to conduct CTi Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates CTi Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct CTi Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain CTi Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine CTi Biopharma's revenue streams: Identify CTi Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research CTi Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish CTi Biopharma's growth potential: Evaluate CTi Biopharma's management, business model, and growth potential.
- Determine CTi Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate CTi Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
CTi Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as CTi Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 114.7 M | |
| Forward Price Earnings | 26.5957 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |